Our research project at a glance
Non-Hodgkin B cell lymphoma (NHL) including chronic lymphocytic leukemia (CLL) are increasingly frequent hematopoietic malignancies. The patients care relies on chemotherapies, immunotherapies and radiotherapy combinations, but relapse and/or unresponsiveness are far too frequent. So our team aims at improving the efficacy of treatments for NHL, notably by assessing immune checkpoint blockade (ICB) in this context.
More specifically, we develop novel tools including analytic methods and biological models to find new molecular pathways for targeting NHL by novel drugs, and assess them in preclinical models, prior to translate our most promising new approaches in Phase l/ll clinical trials of IUC-Toulouse Oncopole.
This includes :
- predicting response of patients to treatment (ibrutinib in CLL, ICB in NHL),
- harnessing innate immunity against lymphoma models,
- development of a humanized anti-TAM mAb neutralizing the stromal support of NHL.
- MALC models
- Deep learning
- Immune checkpoints
- Flow cytometry
Labels and networks
Grants and funders
Oncotarget, 8 (32), pp. 52225-52236, 2017, ISSN: 1949-2553 (Electronic) 1949-2553 (Linking).
Blood Cancer J, 6 (11), pp. e496, 2016, ISSN: 2044-5385 (Electronic) 2044-5385 (Linking).
Blood Cancer J, 6 , pp. e381, 2016, ISSN: 2044-5385 (Electronic) 2044-5385 (Linking).
J Immunol, 196 (1), pp. 493-502, 2016, ISSN: 1550-6606 (Electronic) 0022-1767 (Linking).
Clin Exp Immunol, 186 (3), pp. 277-283, 2016, ISSN: 1365-2249 (Electronic) 0009-9104 (Linking).
Nanomedicine, 12 (8), pp. 2321-2330, 2016, ISSN: 1549-9642 (Electronic) 1549-9634 (Linking).
Oncoimmunology, 5 (7), pp. e1188246, 2016, ISSN: 2162-4011 (Print) 2162-4011 (Linking).
Blood, 126 (11), pp. 1336-45, 2015, ISSN: 1528-0020 (Electronic) 0006-4971 (Linking).